2001
DOI: 10.1182/blood.v98.8.2584
|View full text |Cite
|
Sign up to set email alerts
|

Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
43
1

Year Published

2002
2002
2019
2019

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 52 publications
(44 citation statements)
references
References 18 publications
0
43
1
Order By: Relevance
“…Recently, different groups of investigators have reported the relation between CYP2C9 polymorphisms (ie, CYP2C9*2 and CYP2C9*3) and the daily dose requirement of warfarin and risks of bleeding complications during anticoagulation therapy. [22][23][24][25][26][27][28][29][30][31][32] These studies support an idea that the genetic polymorphisms of CYP2C9 would contribute to the interindividual variability of the anticoagulation responses to warfarin along with the previously known clinical and environmental variables (eg, age, concomitantly administered drugs, foods and clinical indications). 33,34 Our knowledge about pharmacodynamic factors associated with the variability in the anticoagulation of warfarin is relatively limited.…”
Section: Introductionmentioning
confidence: 60%
See 2 more Smart Citations
“…Recently, different groups of investigators have reported the relation between CYP2C9 polymorphisms (ie, CYP2C9*2 and CYP2C9*3) and the daily dose requirement of warfarin and risks of bleeding complications during anticoagulation therapy. [22][23][24][25][26][27][28][29][30][31][32] These studies support an idea that the genetic polymorphisms of CYP2C9 would contribute to the interindividual variability of the anticoagulation responses to warfarin along with the previously known clinical and environmental variables (eg, age, concomitantly administered drugs, foods and clinical indications). 33,34 Our knowledge about pharmacodynamic factors associated with the variability in the anticoagulation of warfarin is relatively limited.…”
Section: Introductionmentioning
confidence: 60%
“…We critically reappraised their findings using their primers originally reported by Stubbins et al 43 and the other primers by Sullivan-Klose et al 44 that were validated by us and others. [12][13][14]16 We found that the nucleotide sequences of the PCR products amplified by the primers of Leung et al 32 and Stubbins et al 43 differed from those amplified by the latter primers 44 and the authentic DNA sequence of CYP2C9 exon 4. Using the latter PCR primers we found no SNPs in exon 4 of CYP2C9 in Japanese patients (unpublished data).…”
Section: Effects Of Cyp2c9 Genotypes On (S)-warfarin Metabolismmentioning
confidence: 70%
See 1 more Smart Citation
“…Recent pharmacogenetic studies showed that variations in genes, especially vitamin-K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 family 2 subfamily C polypeptide 9 (CYP2C9), contributed significantly to differences in warfarin dose requirements among patients, along with clinical and demographic factors [2][3][4][5]. Subsequent to these investigations, in 2007 the US Food and Drug Administration added pharmacogenetic information to the warfarin product label, highlighting the benefits of genotyping individual patients to improve the initial estimate of a reasonable warfarin dose [6].…”
Section: Accuracy Assessment Of Pharmacogenetic Algorithms For Warfarmentioning
confidence: 99%
“…IkeOluwa Lagunju, 1,2 * Olugbemiro Sodeinde, 1,2 and Paul Telfer 3,4 Transcranial Doppler (TCD) ultrasonography helps to identify children with sickle cell disease (SCD) who are at an increased risk of stroke, making primary stroke prevention a reality. A cross-sectional study of 145 Nigerian children aged 3 years with SCD was carried out to describe the pattern of cerebral blood flow (CBF) abnormalities.…”
Section: Prevalence Of Transcranial Doppler Abnormalities In Nigerianmentioning
confidence: 99%